Cargando…

Sustained Accumulation of Blood-Derived Macrophages in the Immune Microenvironment of Patients with Recurrent Glioblastoma after Therapy

SIMPLE SUMMARY: Glioblastoma (GBM) is the most aggressive type of brain cancer and, despite standard treatments, recurrence is inevitable. The immunosuppressive microenvironment, characterized by an intense recruitment of myeloid cells and a low frequency of anti-tumor lymphocytes, hampers the succe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Magri, Sara, Musca, Beatrice, Bonaudo, Camilla, Tushe, Ada, Russo, Maria Giovanna, Masetto, Elena, Zagonel, Vittorina, Lombardi, Giuseppe, Della Puppa, Alessandro, Mandruzzato, Susanna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8699781/ https://www.ncbi.nlm.nih.gov/pubmed/34944798 http://dx.doi.org/10.3390/cancers13246178

Ejemplares similares

The immune cell landscape of glioblastoma patients highlights a myeloid-enriched and immune suppressed microenvironment compared to metastatic brain tumors
por: Musca, Beatrice, et al.
Publicado: (2023)

Longitudinal evolution of the immune suppressive glioma microenvironment in different synchronous lesions during treatment
por: Mandruzzato, Susanna, et al.
Publicado: (2020)

Magnetic Resonance Imaging Correlates of Immune Microenvironment in Glioblastoma
por: Salvalaggio, Alessandro, et al.
Publicado: (2022)

The immunosuppression pathway of tumor‐associated macrophages is controlled by heme oxygenase‐1 in glioblastoma patients
por: Magri, Sara, et al.
Publicado: (2022)

The immune suppressive microenvironment of human gliomas depends on the accumulation of bone marrow-derived macrophages in the center of the lesion
por: Pinton, Laura, et al.
Publicado: (2019)

Myeloid Diagnostic and Prognostic Markers of Immune Suppression in the Blood of Glioma Patients
por: Del Bianco, Paola, et al.
Publicado: (2022)

Urine 2-Hydroxyglutarate in Glioma
por: Lombardi, Giuseppe, et al.
Publicado: (2016)

Targeting of immunosuppressive myeloid cells from glioblastoma patients by modulation of size and surface charge of lipid nanocapsules
por: Pinton, Laura, et al.
Publicado: (2020)

The Combination of Carmustine Wafers and Fotemustine in Recurrent Glioblastoma Patients: A Monoinstitutional Experience
por: Lombardi, Giuseppe, et al.
Publicado: (2014)

An Overview of Intracranial Ependymomas in Adults
por: Lombardi, Giuseppe, et al.
Publicado: (2021)

An Overview of Fotemustine in High-Grade Gliomas: From Single Agent to Association with Bevacizumab
por: Lombardi, Giuseppe, et al.
Publicado: (2014)

Gliomas
por: Lombardi, Giuseppe, et al.
Publicado: (2014)

A New Landscape for Systemic Pharmacotherapy of Recurrent Glioblastoma?
por: Lombardi, Giuseppe, et al.
Publicado: (2020)

Regorafenib in Recurrent Glioblastoma Patients: A Large and Monocentric Real-Life Study
por: Lombardi, Giuseppe, et al.
Publicado: (2021)

Recurrent Glioblastoma: From Molecular Landscape to New Treatment Perspectives
por: Birzu, Cristina, et al.
Publicado: (2020)

Functional outcomes, extent of resection, and bright/vague fluorescence interface in resection of glioblastomas involving the motor pathways assisted by 5-ALA
por: Muscas, Giovanni, et al.
Publicado: (2022)

Validation of the Comprehensive Geriatric Assessment as a Predictor of Mortality in Elderly Glioblastoma Patients
por: Lombardi, Giuseppe, et al.
Publicado: (2019)

Human MDSCs derived from the bone marrow maintain their functional ability but have a reduced frequency of induction in the elderly compared to pediatric donors
por: Magri, Sara, et al.
Publicado: (2020)

Correction to: Human MDSCs derived from the bone marrow maintain their functional ability but have a reduced frequency of induction in the elderly compared to pediatric donors
por: Magri, Sara, et al.
Publicado: (2020)

Annexin 2A sustains glioblastoma cell dissemination and proliferation
por: Maule, Francesca, et al.
Publicado: (2016)

Pembrolizumab Activity in Recurrent High-Grade Gliomas with Partial or Complete Loss of Mismatch Repair Protein Expression: A Monocentric, Observational and Prospective Pilot Study
por: Lombardi, Giuseppe, et al.
Publicado: (2020)

Ocular Side Effects of EGFR-Inhibitor ABT-414 in Recurrent Glioblastoma: A Long-Term Safety Study
por: Parrozzani, Raffaele, et al.
Publicado: (2020)

Collagen VI sustains cell stemness and chemotherapy resistance in glioblastoma
por: Cescon, Matilde, et al.
Publicado: (2023)

Newly Diagnosed Multifocal GBM: A Monocentric Experience and Literature Review
por: Baro, Valentina, et al.
Publicado: (2022)

Treatment of Malignant Gliomas in Elderly Patients: A Concise Overview of the Literature
por: Farina, Patrizia, et al.
Publicado: (2014)

Cognitive Rehabilitation in Patients with Gliomas and Other Brain Tumors: State of the Art
por: Bergo, E., et al.
Publicado: (2016)

Corneal side effects induced by EGFR-inhibitor antibody–drug conjugate ABT-414 in patients with recurrent glioblastoma: a prospective clinical and confocal microscopy study
por: Parrozzani, Raffaele, et al.
Publicado: (2020)

Caring for Patients with Advanced Stage Cancer at the Time of COVID‐19
por: Brunello, Antonella, et al.
Publicado: (2020)

Seizures, Edema, Thrombosis, and Hemorrhages: An Update Review on the Medical Management of Gliomas
por: Zoccarato, Marco, et al.
Publicado: (2021)

BIMG-17. EFFECTS OF THE TUMOUR MICROENVIRONMENT ON PROTOPORPHYRIN IX ACCUMULATION IN GLIOBLASTOMA
por: Walker, Paul, et al.
Publicado: (2021)

Depatuxizumab Mafodotin (Depatux-M) Plus Temozolomide in Recurrent Glioblastoma Patients: Real-World Experience from a Multicenter Study of Italian Association of Neuro-Oncology (AINO)
por: Padovan, Marta, et al.
Publicado: (2021)

Definition of the Prognostic Role of MGMT Promoter Methylation Value by Pyrosequencing in Newly Diagnosed IDH Wild-Type Glioblastoma Patients Treated with Radiochemotherapy: A Large Multicenter Study
por: Caccese, Mario, et al.
Publicado: (2022)

PET/MR in recurrent glioblastoma patients treated with regorafenib: [(18)F]FET and DWI-ADC for response assessment and survival prediction
por: Lombardi, Giuseppe, et al.
Publicado: (2022)

Patterns of gray and white matter functional networks involvement in glioblastoma patients: indirect mapping from clinical MRI scans
por: Sansone, Giulio, et al.
Publicado: (2023)

Early tumour shrinkage as a survival predictor in patients with recurrent glioblastoma treated with bevacizumab in the AVAREG randomized phase II study
por: Brandes, Alba A., et al.
Publicado: (2017)

Ventricular entry during surgical resection is associated with intracranial leptomeningeal dissemination in glioblastoma patients
por: Battista, Francesca, et al.
Publicado: (2022)

Prognostic role and interaction of TERT promoter status, telomere length and MGMT promoter methylation in newly diagnosed IDH wild-type glioblastoma patients
por: Giunco, S., et al.
Publicado: (2023)

Serum Exosomal microRNA-21, 222 and 124-3p as Noninvasive Predictive Biomarkers in Newly Diagnosed High-Grade Gliomas: A Prospective Study
por: Olioso, Debora, et al.
Publicado: (2021)

The role of radiation therapy and systemic treatments in meningioma: The present and the future
por: Caccese, Mario, et al.
Publicado: (2023)

The Three-Layer Concentric Model of Glioblastoma: Cancer Stem Cells, Microenvironmental Regulation, and Therapeutic Implications
por: Persano, Luca, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_h5l2bp4ov4lir45lqv7c14j9rt